Literature DB >> 31783085

Mitochondrial metabolic reprogramming: An important player in liver cancer progression.

Tianqiang Jin1, Chao Wang2, Yu Tian1, Chaoliu Dai1, Yuwen Zhu3, Feng Xu4.   

Abstract

Mitochondria are known as essential biosynthetic, bioenergetic and signaling organelles, and play a critical role in cell differentiation, proliferation, and death. Nowadays, cancer is emergingly considered as a mitochondrial metabolic disease. Mitochondria also play an essential role in liver carcinogenesis. Liver cells are highly regenerative and require high energy. For that reason, a large number of mitochondria are present and functional in liver cells. Abnormalities in mitochondrial metabolism in human liver are known to be one of the carcinogenic factors. Interestingly, immune checkpoints regulate mitochondrial metabolic energetics of the tumor, the tumor microenvironment, as well as the tumor-specific immune response. This regulation forms a positive loop between the metabolic reprogramming of both cancer cells and immune cells. In this review, we discuss the evidence and mechanisms that mitochondria interplay with immune checkpoints to influence different steps of oncogenesis, as well as the potential of mitochondria as therapeutic targets for liver cancer therapy.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immune checkpoint; Liver cancer; Mitochondria; Therapeutic target

Mesh:

Substances:

Year:  2019        PMID: 31783085     DOI: 10.1016/j.canlet.2019.11.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Downregulation of a mitochondrial micropeptide, MPM, promotes hepatoma metastasis by enhancing mitochondrial complex I activity.

Authors:  Man-Huan Xiao; Yi-Fang Lin; Peng-Peng Xie; Hua-Xing Chen; Jun-Wen Deng; Wei Zhang; Na Zhao; Chen Xie; Yu Meng; Xingguo Liu; Shi-Mei Zhuang; Ying Zhu; Jian-Hong Fang
Journal:  Mol Ther       Date:  2021-09-01       Impact factor: 11.454

2.  Melatonin Targets Metabolism in Head and Neck Cancer Cells by Regulating Mitochondrial Structure and Function.

Authors:  Ana Guerra-Librero; Beatriz I Fernandez-Gil; Javier Florido; Laura Martinez-Ruiz; César Rodríguez-Santana; Ying-Qiang Shen; José M García-Verdugo; Alba López-Rodríguez; Iryna Rusanova; Alfredo Quiñones-Hinojosa; Darío Acuña-Castroviejo; Jordi Marruecos; Tomás De Haro; Germaine Escames
Journal:  Antioxidants (Basel)       Date:  2021-04-14

3.  A metabolism-related gene signature for predicting the prognosis and therapeutic responses in patients with hepatocellular carcinoma.

Authors:  Xiaoyan Dai; Wei Jiang; Liang Ma; Jie Sun; Xiaodi Yan; Jing Qian; Yan Wang; Yu Shi; Shujie Ni; Ninghua Yao
Journal:  Ann Transl Med       Date:  2021-03

4.  Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy.

Authors:  Junjie Shen; Jingfang Liu; Peng Sun; Zaixiang Tang; Huijun Li; Lu Bai; Zixuan Du; Ruirui Geng; Jianping Cao
Journal:  Radiat Oncol       Date:  2021-11-18       Impact factor: 3.481

5.  Metabolism-Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53-Mutant Colon Cancer.

Authors:  Meng Tang; Hui Xu; Hongyan Huang; Hao Kuang; Chenxi Wang; Qinqin Li; Xin Zhang; Yizhong Ge; Mengmeng Song; Xi Zhang; Ziwen Wang; Chaobing Ma; Jinlin Kang; Wanfang Zhang; You Wang; Bo Zhang; Xiaowei Zhang; Yongbing Chen; Minghua Cong; Gerry Melino; Xiaobin Wang; Fuxiang Zhou; Qiang Sun; Hanping Shi
Journal:  Adv Sci (Weinh)       Date:  2022-08-28       Impact factor: 17.521

6.  Biodegradable hollow mesoporous organosilica nanotheranostics (HMON) for multi-mode imaging and mild photo-therapeutic-induced mitochondrial damage on gastric cancer.

Authors:  Weihong Guo; Zhian Chen; Jiajia Chen; Xiaoli Feng; Yang Yang; Huilin Huang; Yanrui Liang; Guodong Shen; Yu Liang; Chao Peng; Yanbing Li; Guoxin Li; Wenhua Huang; Bingxia Zhao; Yanfeng Hu
Journal:  J Nanobiotechnology       Date:  2020-07-20       Impact factor: 10.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.